longbridgelongbridge
  • Products
  • Fees
  • Download
  • Promotions
    Welcome RewardsReferral ProgramUS Pre-Market Options Trading
  • For Institutions
    Corporate ServicesDevelopers
  • Help
  • About
    About LongbridgeLicense & RegulatoryMedia CoverageJoin Us
longbridge
  • Home
  • Discover
    Discover
    Global MarketsStock ScreenerFinancial Calendar
  • News & Info
    News & Info
    NewsInsightsLiveAcademy
  • Watchlist
  • Trade
  • Notification
  • LongbridgeAI
Home
Discover
News & Info
Watchlist
Trade
LongbridgeAI
Quote ListQuote List

Nuvation Bio(NUVB.US)

Last Updated 19:00:00 ET
longbridge loading
News
Financials
Overview

How Does Nuvation Bio’s (NUVB) IBTROZI Update Reframe Its Long-Term Oncology Investment Narrative?

Simplywall·6 Hours ago
US
NUVB
+6.37%
US
TMO
+0.89%
US
BIB
+4.98%
Simplywall·6 Hours ago
US
NUVB
+6.37%
US
TMO
+0.89%
US
BIB
+4.98%

Nuvation Bio to Collaborate with Thermo Fisher Scientific for U.S.-Based Manufacturing of IBTROZI® for ROS1-Positive Non-Small Cell Lung Cancer | NUVB Stock News

StockTitan·05/13/2026 20:05
US
TMO
+0.89%
US
NUVB
+6.37%
US
IXJ
+0.35%
StockTitan·05/13/2026 20:05
US
TMO
+0.89%
US
NUVB
+6.37%
US
IXJ
+0.35%

Nuvation Bio to Participate in Upcoming Investor Conferences

Unusual Whales·05/06/2026 04:08
US
NUVB
+6.37%
US
BIB
+4.98%
US
PBE
+1.60%
Unusual Whales·05/06/2026 04:08
US
NUVB
+6.37%
US
BIB
+4.98%
US
PBE
+1.60%

Nuvation Bio shares are trading higher after the company reported in-line Q1 EPS results and better-than-expected sales results.

benzinga_article·05/06/2026 02:14
US
NUVB
+6.37%
US
XLV
-0.13%
US
FBT
+2.14%
benzinga_article·05/06/2026 02:14
US
NUVB
+6.37%
US
XLV
-0.13%
US
FBT
+2.14%

Wedbush Keeps Their Buy Rating on Nuvation Bio (NUVB)

Tip Ranks·05/05/2026 21:47
US
NUVB
+6.37%
US
PBE
+1.60%
US
SBIO
+3.75%
Tip Ranks·05/05/2026 21:47
US
NUVB
+6.37%
US
PBE
+1.60%
US
SBIO
+3.75%
© 2026 Longbridge|Disclaimer

Event Tracking

May6
Nuvation Bio's supplemental new drug application accepted by FDA
12:07
May4
Nuvation Bio released FY2026 Q1 earnings on May 4 After-Market EST, actual revenue USD 83.23 M (forecast USD 62.34 M), actual EPS USD 0.0155 (forecast USD -0.0004)
23:00
Apr27
Nuvation Bio to Release FY2026 Q1 Earnings on May 4 After-Market EST, Forecast Revenue USD 64.81 M, EPS USD -0.0004
00:20
Apr20
Nuvation Bio Highlights IBTROZI's Potential in ROS1+ NSCLC Treatment
21:51
Mar3
Nuvation Bio released FY2025 annual earnings on March 2 After-Market EST, actual revenue USD 62.9 M (forecast USD 58.55 M), actual EPS USD -0.5991 (forecast USD -0.5888)
00:00
Nuvation Bio released FY2025 Q4 earnings on March 2 After-Market (EST), actual revenue USD 41.87 M (forecast USD 37.5 M), actual EPS USD -0.11 (forecast USD -0.0896)
00:00

Schedules & Filings

Schedules
Filings
May4
Earning Release(EST)

FY2026 Q1 Earning Release (USD) Revenue 83.23 M, Net Income 5.397 M, EPS 0.0155

Mar2
Earning Release(EST)

FY2025 Q4 Earning Release (USD) Revenue 41.87 M, Net Income -36.59 M, EPS -0.1062

Nov3
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 13.12 M, Net Income -55.79 M, EPS -0.1629

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
OPTH
6.080
+2,485.03%
+5.845
HCWB
2.430
+129.25%
+1.370
SLXN
0.5298
+96.95%
+0.261
VIDA
4.150
+81.22%
+1.860
GCL
0.7445
+72.46%
+0.313
PHGE
0.5969
+59.60%
+0.223
MTVA
2.890
+53.72%
+1.010
MWC
7.150
+51.48%
+2.430
PETZ
1.150
+41.98%
+0.340
MLGO
5.360
+39.95%
+1.530
View More